Latest Close
$7.07
Stock Hub
FHTX
Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. Use the sections below to move between chart, technical analysis, fundamentals, and news.
1y Change
$1.51 (+27.16%)
Market Cap
$419,854,208.00
Sector
Healthcare
Industry
Biotechnology
Recommendation
strong_buy
52W Range
$3.27 to $7.61
Target Mean Price
$11.44
Beta
2.83
Trailing P/E
Not available
Forward P/E
-6.87
Price / Book
Not available
Company Overview
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.